The serotonergic system in ageing and Alzheimer's disease

Progress in Neurobiology

Volumn 99, Issue 1, 2012, Pages 15-41

  Rodríguez, José Julio ^a,b,c,d   Noristani, Harun N ^e   Verkhratsky, Alexei ^a,b,c,e  

^a BASQUE FOUNDATION FOR SCIENCE   (Spain)

^b BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alzheimer's disease; Dementia; Hippocampus; Plasticity; Raphe nucleus; Serotonin; Serotonin receptors; Serotonin transporter

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; AS 19; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; GLUTAMIC ACID; MONOAMINE OXIDASE INHIBITOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NOOTROPIC AGENT; ONDANSETRON; SB 258585; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 3 AGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN 7 AGONIST; SEROTONIN 7 RECEPTOR; SEROTONIN AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ATTENTION; BRAIN FUNCTION; BRAIN REGION; CHOLINERGIC TRANSMISSION; COGNITION; DEGENERATIVE DISEASE; DEPRESSION; DOPAMINERGIC TRANSMISSION; DRUG TARGETING; EXCITOTOXICITY; FRONTOTEMPORAL DEMENTIA; GABAERGIC TRANSMISSION; GLUTAMATERGIC TRANSMISSION; HUMAN; LEARNING; LEARNING DISORDER; LONG TERM MEMORY; LONG TERM POTENTIATION; MEMORY CONSOLIDATION; MEMORY DISORDER; MENTAL STRESS; MOOD DISORDER; NERVE PROJECTION; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; SHORT TERM MEMORY; SPATIAL MEMORY; WORKING MEMORY;

AGING; ALZHEIMER DISEASE; BRAIN; HUMANS; SEROTONERGIC NEURONS; SEROTONIN;

EID: 84866565986     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.06.010     Document Type: Review

References (487)

1. Abe Y., Aoyagi A., Hara T., Abe K., Yamazaki R., Kumagae Y., Naruto S., Koyama K., Marumoto S., Tago K., Toda N., Takami K., Yamada N., Ori M., Kogen H., Kaneko T. Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease. Journal of Pharmacological Sciences 2003, 93:95-105.
2. 2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology 1999, 20:92-96.
3. Aboukhatwa M., Dosanjh L., Luo Y. Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. Molecular Neurodegeneration 2010, 5:10.
4. 2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Research 1999, 825:161-171.
5. Aletrino M.A., Vogels O.J., Van Domburg P.H., Ten Donkelaar H.J. Cell loss in the nucleus raphes dorsalis in Alzheimer's disease. Neurobiology of Aging 1992, 13:461-468.
6. 2 receptors. Neuropharmacology 1993, 32:1427-1432.
7. Alves S.E., Hoskin E., Lee S.J., Brake W.G., Ferguson D., Luine V., Allen P.B., Greengard P., McEwen B.S. Serotonin mediates CA1 spine density but is not crucial for ovarian steroid regulation of synaptic plasticity in the adult rat dorsal hippocampus. Synapse 2002, 45:143-151.
8. Alzheimer A. über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin 1907, 64:146-148.
9. Amaral D.G., Kurz J. An analysis of the origins of the cholinergic and noncholinergic septal projections to the hippocampal formation of the rat. The Journal of Comparative Neurology 1985, 240:37-59.
10. Amin A.H., Crawford T.B., Gaddum J.H. The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog. The Journal of Physiology 1954, 126:596-618.
11. 2C serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Research 2002, 951:135-140.
12. 3 receptor antagonists on cognitive performance in aged monkeys. Neurobiology of Aging 1997, 18:21-28.
13. Arranz B., Eriksson A., Mellerup E., Plenge P., Marcusson J. Effect of aging in human cortical pre- and postsynaptic serotonin binding sites. Brain Research 1993, 620:163-166.
14. Arvidsson L.E., Hacksell U., Nilsson J.L., Hjorth S., Carlsson A., Lindberg P., Sanchez D., Wikstrom H. 8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. Journal of Medicinal Chemistry 1981, 24:921-923.
15. Assal F., Alarcon M., Solomon E.C., Masterman D., Geschwind D.H., Cummings J.L. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Archives of Neurology 2004, 61:1249-1253.
16. Azmitia E.C. Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Research Bulletin 2001, 56:413-424.
17. Azmitia E.C., Dolan K., Whitaker-Azmitia P.M. S-100B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor. Brain Research 1990, 516:354-356.
18. Azmitia E.C., Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. The Journal of Comparative Neurology 1978, 179:641-667.
19. Aznar S., Klein A.B., Santini M.A., Knudsen G.M., Henn F., Gass P., Vollmayr B. Aging and depression vulnerability interaction results in decreased serotonin innervation associated with reduced BDNF levels in hippocampus of rats bred for learned helplessness. Synapse 2010, 64:561-565.
20. 7 receptor: role in novel object discrimination and relation to novelty-seeking behavior. Neuroscience 2007, 149:192-202.
21. Baker K.G., Halliday G.M., Tork I. Cytoarchitecture of the human dorsal raphe nucleus. The Journal of Comparative Neurology 1990, 301:147-161.
22. Barnes N.M., Costall B., Naylor R.J., Williams T.J., Wischik C.M. Normal densities of 5-HT3 receptor recognition sites in Alzheimer's disease. Neuroreport 1990, 1:253-254.
23. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
24. Behan M., Brownfield M.S. Age-related changes in serotonin in the hypoglossal nucleus of rat: implications for sleep-disordered breathing. Neuroscience Letters 1999, 267:133-136.
25. Benninghoff J., Gritti A., Rizzi M., Lamorte G., Schloesser R.J., Schmitt A., Robel S., Genius J., Moessner R., Riederer P., Manji H.K., Grunze H., Rujescu D., Moeller H.J., Lesch K.P., Vescovi A.L. Serotonin depletion hampers survival and proliferation in neurospheres derived from adult neural stem cells. Neuropsychopharmacology 2010, 35:893-903.
26. Bernedo V., Insua D., Suarez M.L., Santamarina G., Sarasa M., Pesini P. β-amyloid cortical deposits are accompanied by the loss of serotonergic neurons in the dog. The Journal of Comparative Neurology 2009, 513:417-429.
27. Bertel O., Malessa S., Sluga E., Hornykiewicz O. Amyotrophic lateral sclerosis: changes of noradrenergic and serotonergic transmitter systems in the spinal cord. Brain Research 1991, 566:54-60.
28. Bertrand F., Lehmann O., Lazarus C., Jeltsch H., Cassel J.C. Intraseptal infusions of 8-OH-DPAT in the rat impairs water-maze performances: effects on memory or anxiety?. Neuroscience Letters 2000, 279:45-48.
29. Bhaskaran D., Radha E. Monoamine levels and monoamine oxidase activity in different regions of rat brain as a function of age. Mechanisms of Ageing and Development 1983, 23:151-160.
30. 2 receptors on human blood platelets. Psychopharmacology 1992, 108:210-212.
31. Bigham M.H., Lidow M.S. Adrenergic and serotonergic receptors in aged monkey neocortex. Neurobiology of Aging 1995, 16:91-104.
32. Birks J.S., Melzer D. Donepezil for mild and moderate Alzheimer's disease. Cochrane Database of Systematic Reviews 2000, 2:CD001190.
33. Birthelmer A., Lazaris A., Schweizer T., Jackisch R., Cassel J.C. Presynaptic regulation of neurotransmitter release in the cortex of aged rats with differential memory impairments. Pharmacology, Biochemistry, and Behavior 2003, 75:147-162.
34. Birthelmer A., Stemmelin J., Jackisch R., Cassel J.C. Presynaptic modulation of acetylcholine, noradrenaline, and serotonin release in the hippocampus of aged rats with various levels of memory impairments. Brain Research Bulletin 2003, 60:283-296.
35. Bjarkam C.R., Sorensen J.C., Geneser F.A. Distribution and morphology of serotonin-immunoreactive axons in the retrohippocampal areas of the New Zealand white rabbit. Anatomy and Embryology 2005, 210:199-207.
36. Bjork K., Sjogren B., Svenningsson P. Regulation of serotonin receptor function in the nervous system by lipid rafts and adaptor proteins. Experimental Cell Research 2010, 316:1351-1356.
37. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
38. 2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. Brain 1993, 116(Pt 3):497-510.
39. Bogdanski D.F., Pletscher A., Brodie B.B., Undenfriend S. Identification and assay of serotonin in brain. The Journal of Pharmacology and Experimental Therapeutics 1956, 117:82-88.
40. 1A receptor in relation to human cognition. Behavioural Brain Research 2008, 195:103-111.
41. Borroni B., Grassi M., Agosti C., Costanzi C., Archetti S., Franzoni S., Caltagirone C., Di Luca M., Caimi L., Padovani A. Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT, 5-HTTLPR and APOE polymorphisms. Neurobiology of Aging 2006, 27:1595-1603.
42. Bowen D.M., Allen S.J., Benton J.S., Goodhardt M.J., Haan E.A., Palmer A.M., Sims N.R., Smith C.C., Spillane J.A., Esiri M.M., Neary D., Snowdon J.S., Wilcock G.K., Davison A.N. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. Journal of Neurochemistry 1983, 41:266-272.
43. Bowen D.M., Procter A.W., Mann D.M., Snowden J.S., Esiri M.M., Neary D., Francis P.T. Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. Psychopharmacology 2008, 196:603-610.
44. Bowen D.M., Smith C.B., White P., Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976, 99:459-496.
45. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991, 82:239-259.
46. Bradley P.B., Engel G., Feniuk W., Fozard J.R., Humphrey P.P., Middlemiss D.N., Mylecharane E.J., Richardson B.P., Saxena P.R. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986, 25:563-576.
47. Brayne C., Gill C., Huppert F.A., Barkley C., Gehlhaar E., Girling D.M., O'Connor D.W., Paykel E.S. Incidence of clinically diagnosed subtypes of dementia in an elderly population. Cambridge project for later life. The British Journal of Psychiatry: the Journal of Mental Science 1995, 167:255-262.
48. Brezun J.M., Daszuta A. Depletion in serotonin decreases neurogenesis in the dentate gyrus and the subventricular zone of adult rats. Neuroscience 1999, 89:999-1002.
49. Brezun J.M., Daszuta A. Serotonergic reinnervation reverses lesion-induced decreases in PSA-NCAM labeling and proliferation of hippocampal cells in adult rats. Hippocampus 2000, 10:37-46.
50. Brezun J.M., Daszuta A. Serotonin may stimulate granule cell proliferation in the adult hippocampus, as observed in rats grafted with foetal raphe neurons. The European Journal of Neuroscience 2000, 12:391-396.
51. 2+ influx induced by β-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. Journal of Neurobiology 1995, 26:325-338.
52. 3H]imipramine binding sites in rat cerebral cortex. European Journal of Pharmacology 1985, 110:393-394.
53. Bucht G., Adolfsson R., Gottfries C.G., Roos B.E., Winblad B. Distribution of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in human brain in relation to age, drug influence, agonal status and circadian variation. Journal of Neural Transmission 1981, 51:185-203.
54. Buhot M.C. Serotonin receptors in cognitive behaviors. Current Opinion in Neurobiology 1997, 7:243-254.
55. Buhot M.C., Martin S., Segu L. Role of serotonin in memory impairment. Annals of Medicine 2000, 32:210-221.
56. Burke W.J., Chung H.D., Huang J.S., Huang S.S., Haring J.H., Strong R., Marshall G.L., Joh T.H. Evidence for retrograde degeneration of epinephrine neurons in Alzheimer's disease. Annals of Neurology 1988, 24:532-536.
57. Burke W.J., Park D.H., Chung H.D., Marshall G.L., Haring J.H., Joh T.H. Evidence for decreased transport of tryptophan hydroxylase in Alzheimer's disease. Brain Research 1990, 537:83-87.
58. Butters M.A., Becker J.T., Nebes R.D., Zmuda M.D., Mulsant B.H., Pollock B.G., Reynolds C.F. Changes in cognitive functioning following treatment of late-life depression. The American Journal of Psychiatry 2000, 157:1949-1954.
59. 4 receptor agonists increase sAPPα levels in the cortex and hippocampus of male C57BL/6j mice. British Journal of Pharmacology 2007, 150:883-892.
60. Carey G.J., Costall B., Domeney A.M., Gerrard P.A., Jones D.N., Naylor R.J., Tyers M.B. Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset. Pharmacology, Biochemistry, and Behavior 1992, 42:75-83.
61. 1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal administration of scopolamine or 7-chloro-kynurenic acid. Brain Research 1997, 774:167-174.
62. 1A receptors in the dorsal raphe reverses the impairment of spatial learning caused by intrahippocampal scopolamine in rats. The European Journal of Neuroscience 1998, 10:221-230.
63. 1A receptors in the dorsal hippocampus impairs acquisition and performance of a spatial task in a water maze. Brain Research 1992, 595:50-56.
64. 1A receptors. British Journal of Pharmacology 1992, 105:720-726.
65. 1A receptor agonist, impairs performance in a passive avoidance task. European Journal of Pharmacology 1992, 211:227-234.
66. Cassel J.C., Jeltsch H. Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Neuroscience 1995, 69:1-41.
67. Chan J., Aoki C., Pickel V.M. Optimization of differential immunogold-silver and peroxidase labeling with maintenance of ultrastructure in brain sections before plastic embedding. Journal of Neuroscience Methods 1990, 33:113-127.
68. Chen C.P., Alder J.T., Bowen D.M., Esiri M.M., McDonald B., Hope T., Jobst K.A., Francis P.T. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. Journal of Neurochemistry 1996, 66:1592-1598.
69. Chen C.P., Eastwood S.L., Hope T., McDonald B., Francis P.T., Esiri M.M. Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropathology and Applied Neurobiology 2000, 26:347-355.
70. Cheng A.V., Ferrier I.N., Morris C.M., Jabeen S., Sahgal A., McKeith I.G., Edwardson J.A., Perry R.H., Perry E.K. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. Journal of the Neurological Sciences 1991, 106:50-55.
71. 4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Experimental Neurology 2007, 203:274-278.
72. Choi I.S., Cho J.H., Kim J.T., Park E.J., Lee M.G., Shin H.I., Choi B.J., Jang I.S. Serotoninergic modulation of GABAergic synaptic transmission in developing rat CA3 pyramidal neurons. Journal of Neurochemistry 2007, 103:2342-2353.
73. 2A levels. Experimental Neurology 2008, 210:164-171.
74. Cidis Meltzer C., Drevets W.C., Price J.C., Mathis C.A., Lopresti B., Greer P.J., Villemagne V.L., Holt D., Mason N.S., Houck P.R., Reynolds C.F., DeKosky S.T. Gender-specific aging effects on the serotonin 1A receptor. Brain Research 2001, 895:9-17.
75. Cirrito J.R., Disabato B.M., Restivo J.L., Verges D.K., Goebel W.D., Sathyan A., Hayreh D., D'Angelo G., Benzinger T., Yoon H., Kim J., Morris J.C., Mintun M.A., Sheline Y.I. Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:14968-14973.
76. Clegg A., Bryant J., Nicholson T., McIntyre L., De Broe S., Gerard K., Waugh N. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technology Assessment 2001, 5:1-137.
77. Clinton L.K., Billings L.M., Green K.N., Caccamo A., Ngo J., Oddo S., McGaugh J.L., LaFerla F.M. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiology of Disease 2007, 28:76-82.
78. Coggeshall R.E., Lekan H.A. Methods for determining numbers of cells and synapses: a case for more uniform standards of review. The Journal of Comparative Neurology 1996, 364:6-15.
79. Consolo S., Arnaboldi S., Giorgi S., Russi G., Ladinsky H. 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport 1994, 5:1230-1232.
80. Cools R., Roberts A.C., Robbins T.W. Serotoninergic regulation of emotional and behavioural control processes. Trends in Cognitive Sciences 2008, 12:31-40.
81. Cornea-Hebert V., Riad M., Wu C., Singh S.K., Descarries L. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. The Journal of Comparative Neurology 1999, 409:187-209.
82. Cross A.J., Crow T.J., Ferrier I.N., Johnson J.A. The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia. Neurobiology of Aging 1986, 7:3-7.
83. Cross A.J., Crow T.J., Ferrier I.N., Johnson J.A., Bloom S.R., Corsellis J.A. Serotonin receptor changes in dementia of the Alzheimer type. Journal of Neurochemistry 1984, 43:1574-1581.
84. Cross A.J., Slater P., Perry E.K., Perry R.H. An autoradiographic analysis of serotonin receptors in human temporal cortex: changes in Alzheimer-type dementia. Neurochemistry International 1988, 13:89-96.
85. Crow T.J., Cross A.J., Cooper S.J., Deakin J.F., Ferrier I.N., Johnson J.A., Joseph M.H., Owen F., Poulter M., Lofthouse R., et al. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 1984, 23:1561-1569.
86. Cumming T., Brodtmann A. Dementia and stroke: the present and future epidemic. International Journal of Stroke 2010, 5:453-454.
87. Curcio C.A., Kemper T. Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density. Journal of Neuropathology and Experimental Neurology 1984, 43:359-368.
88. Dahlström A., Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiologica Scandinavica 1964, 62(Suppl. 55).
89. Davidoff M.S., Lolova I.S. Age-related changes in serotonin-immunoreactivity in the telencephalon and diencephalon of rats. Jurnal fur Hirnforschung 1991, 32:745-753.
90. 6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 2001, 25:662-668.
91. 2A receptors in human and monkey prefrontal cortex. Journal of Neurochemistry 2007, 103:475-486.
92. de Sola Llopis S., Miguelez-Pan M., Pena-Casanova J., Poudevida S., Farre M., Pacifici R., Bohm P., Abanades S., Verdejo Garcia A., Langohr K., Zuccaro P., de la Torre R. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. Journal of Psychopharmacology 2008, 22:498-510.
93. de Vasconcelos Cunha U.G., Lopes Rocha F., Avila de Melo R., Alves Valle E., de Souza Neto J.J., Mendes Brega R., Magalhaes Scoralick F., Araujo Silva S., Martins de Oliveira F., da Costa Junior A.L., Faria Alves V.X., Sakurai E. A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dementia and Geriatric Cognition Disorders 2007, 24:36-41.
94. Deakin J.B., Rahman S., Nestor P.J., Hodges J.R., Sahakian B.J. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology 2004, 172:400-408.
95. Descarries L., Cornea-Hébert V., Riad M. Cellular and subcellular localization of serotonin receptors in the central nervous system. The Serotonin Receptors: From Molecular Pharmacology to Human Therapeutics 2006, 277-317. Humana Press, Totowa, NJ. B.L. Roth (Ed.).
96. 2 receptors in dementia of Alzheimer type: a quantitative autoradiographic study of frontal cortex and hippocampus. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 1990, 2:129-137.
97. Di Carlo A., Baldereschi M., Amaducci L., Lepore V., Bracco L., Maggi S., Bonaiuto S., Perissinotto E., Scarlato G., Farchi G., Inzitari D. Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study. Journal of the American Geriatrics Society 2002, 50:41-48.
98. Dickerson B.C., Bakkour A., Salat D.H., Feczko E., Pacheco J., Greve D.N., Grodstein F., Wright C.I., Blacker D., Rosas H.D., Sperling R.A., Atri A., Growdon J.H., Hyman B.T., Morris J.C., Fischl B., Buckner R.L. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cerebral Cortex 2009, 19:497-510.
99. Dillon K.A., Gross-Isseroff R., Israeli M., Biegon A. Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: effects of age and alcohol. Brain Research 1991, 554:56-64.
100. Dogrul A., Ossipov M.H., Porreca F. Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors. Brain Reserach 2009, 1280:52-59.
101. Dringenberg H.C. Alzheimer's disease: more than a 'cholinergic disorder' - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behavioural Brain Research 2000, 115:235-249.
102. Dryden S., Frankish H.M., Wang Q., Williams G. Increased feeding and neuropeptide Y (NPY) but not NPY mRNA levels in the hypothalamus of the rat following central administration of the serotonin synthesis inhibitor p-chlorophenylalanine. Brain Research 1996, 724:232-237.
103. 7 receptor mRNA in the hamster brain: effect of aging and association with calbindin-D28K expression. Brain Research 2007, 1143:70-77.
104. 1A receptors in discrete regions of the circadian timing system in hamsters. Brain Research 1999, 829:39-45.
105. Duyckaerts C., Delatour B., Potier M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathologica 2009, 118:5-36.
106. Ebinger G., Bruyland M., Martin J.J., Herregodts P., Cras P., Michotte Y., Gomme L. Distribution of biogenic amines and their catabolites in brains from patients with Alzheimer's disease. Journal of the Neurological Sciences 1987, 77:267-283.
107. 1A receptor-mediated inhibition of long-term potentiation in rat visual cortex. European Journal of Pharmacology 1998, 349:221-224.
108. 1A receptors in the dorsal hippocampus in rats. Brain Research 2006, 1069:54-62.
109. 2A receptors is associated with large vessel infarction and relative preservation of cognition. Brain 2009, 132:1858-1865.
110. 1A and NMDA receptors interact in the rat medial septum and modulate hippocampal-dependent spatial learning. Hippocampus 2009, 19:1187-1198.
111. 1A receptor stimulation on contextual learning in mice. European Journal of Pharmacology 2008, 596:107-110.
112. Erspamer V., Asero B. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 1952, 169:800-801.
113. Evers E.A., van der Veen F.M., Fekkes D., Jolles J. Serotonin and cognitive flexibility: neuroimaging studies into the effect of acute tryptophan depletion in healthy volunteers. Current Medicinal Chemistry 2007, 14:2989-2995.
114. Feuerstein T.J. Presynaptic receptors for dopamine, histamine, and serotonin. Handbook of Experimental Pharmacology 2008, 289-338.
115. Fibiger H.C. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends in Neurosciences 1991, 14:220-223.
116. Finkel S.I., Mintzer J.E., Dysken M., Krishnan K.R., Burt T., McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. International Journal of Geriatric Psychiatry 2004, 19:9-18.
117. Flachaire E., Beney C., Berthier A., Salandre J., Quincy C., Renaud B. Determination of reference values for serotonin concentration in platelets of healthy newborns, children, adults, and elderly subjects by HPLC with electrochemical detection. Clinical Chemistry 1990, 36:2117-2120.
118. 6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 2004, 29:93-100.
119. Forero D.A., Arboleda G., Yunis J.J., Pardo R., Arboleda H. Association study of polymorphisms in LRP1, tau and 5-HTT genes and Alzheimer's disease in a sample of Colombian patients. Journal of Neural Transmission 2006, 113:1253-1262.
120. Forrest V., Ince P., Leitch M., Marshall E.F., Shaw P.J. Serotonergic neurotransmission in the spinal cord and motor cortex of patients with motor neuron disease and controls: quantitative autoradiography for 5-HT1a and 5-HT2 receptors. Journal of the Neurological Sciences 1996, 139(Suppl.):83-90.
121. Fowler C.J., Wiberg A., Oreland L., Marcusson J., Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. Journal of Neural Transmission 1980, 49:1-20.
122. Franceschi M., Anchisi D., Pelati O., Zuffi M., Matarrese M., Moresco R.M., Fazio F., Perani D. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Annals of Neurology 2005, 57:216-225.
123. Frazer M.E., Hughes J.E., Mastrangelo M.A., Tibbens J.L., Federoff H.J., Bowers W.J. Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4. Molecular Therapy 2008, 16:845-853.
124. Gaddum J.H., Hameed K.A. Drugs which antagonize 5-hydroxytryptamine. British Journal of Pharmacology and Chemotherapy 1954, 9:240-248.
125. Gaddum J.H., Picarelli Z.P. Two kinds of tryptamine receptor. British Journal of Pharmacology and Chemotherapy 1957, 12:323-328.
126. 4 receptors in the mouse passive avoidance test. The Journal of Pharmacology and Experimental Therapeutics 1998, 286:1115-1121.
127. Garcia-Alloza M., Gil-Bea F.J., Diez-Ariza M., Chen C.P., Francis P.T., Lasheras B., Ramirez M.J. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005, 43:442-449.
128. 6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacology 2004, 29:410-416.
129. Garcia-Alloza M., Zaldua N., Diez-Ariza M., Marcos B., Lasheras B., Javier Gil-Bea F., Ramirez M.J. Effect of selective cholinergic denervation on the serotonergic system: implications for learning and memory. Journal of Neuropathology and Experimental Neurology 2006, 65:1074-1081.
130. Garibotto V., Borroni B., Agosti C., Premi E., Alberici A., Eickhoff S.B., Brambati S.M., Bellelli G., Gasparotti R., Perani D., Padovani A. Subcortical and deep cortical atrophy in frontotemporal lobar degeneration. Neurobiology of Aging 2010, 32:875-884.
131. 7 antagonist SB-269970 in the modulation of working and reference memory in the rat. Behavioural Brain Research 2008, 195:164-170.
132. Gasser U.E., Dravid A.R. Noradrenergic, serotonergic, and cholinergic sprouting in the hippocampus that follows partial or complete transection of the septohippocampal pathway: contributions of spared inputs. Experimental Neurology 1987, 96:352-364.
133. Geddes J.W., Anderson K.J., Cotman C.W. Senile plaques as aberrant sprout-stimulating structures. Experimental Neurology 1986, 94:767-776.
134. 6 receptor antagonists for the treatment of Alzheimer's disease. Current Topics in Medicinal Chemistry 2008, 8:1035-1048.
135. Geldmacher D.S., Whitehouse P.J. Evaluation of dementia. The New England Journal of Medicine 1996, 335:330-336.
136. German D.C., White C.L., Sparkman D.R. Alzheimer's disease: neurofibrillary tangles in nuclei that project to the cerebral cortex. Neuroscience 1987, 21:305-312.
137. Gottfries C.G. Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia. Journal of Neural Transmission. Supplementum 1990, 30:33-43.
138. Gotz J., Schild A., Hoerndli F., Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. International Journal of Developmental Neuroscience 2004, 22:453-465.
139. Green A.R. Neuropharmacology of 5-hydroxytryptamine. British Journal of Pharmacology 2006, 147(Suppl. 1):S145-S152.
140. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:7611-7615.
141. 2 receptors of the human brain postmortem. Brain Research 1990, 519:223-227.
142. Grudzien A., Shaw P., Weintraub S., Bigio E., Mash D.C., Mesulam M.M. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiology of Aging 2007, 28:327-335.
143. Gulesserian T., Engidawork E., Cairns N., Lubec G. Increased protein levels of serotonin transporter in frontal cortex of patients with Down syndrome. Neuroscience Letters 2000, 296:53-57.
144. Haider S., Khaliq S., Ahmed S.P., Haleem D.J. Long-term tryptophan administration enhances cognitive performance and increases 5HT metabolism in the hippocampus of female rats. Amino Acids 2006, 31:421-425.
145. Haider S., Khaliq S., Haleem D.J. Enhanced serotonergic neurotransmission in the hippocampus following tryptophan administration improves learning acquisition and memory consolidation in rats. Pharmacological Reports 2007, 59:53-57.
146. Hajszan T., MacLusky N.J., Leranth C. Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. The European Journal of Neuroscience 2005, 21:1299-1303.
147. Halliday G.M., McCann H.L., Pamphlett R., Brooks W.S., Creasey H., McCusker E., Cotton R.G., Broe G.A., Harper C.G. Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. Acta Neuropathologica 1992, 84:638-650.
148. 3H]5-HT binding in the CNS of female Fischer 344 rats. Neuroscience Letters 1989, 101:293-298.
149. Hansson G., Alafuzoff I., Winblad B., Marcusson J. Intact brain serotonin system in vascular dementia. Dementia 1996, 7:196-200.
150. 1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. Psychopharmacology 1996, 127:245-254.
151. 1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology 2000, 39:547-552.
152. Hardy J.A., Mann D.M., Wester P., Winblad B. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiology of Aging 1986, 7:489-502.
153. 2+ antagonist nimodipine. Neuroscience 2000, 101:101-114.
154. 1-42-induced cholinergic lesions in rat nucleus basalis bidirectionally modulate serotonergic innervation of the basal forebrain and cerebral cortex. Neurobiology of Disease 2001, 8:667-678.
155. Harmer C.J., Bhagwagar Z., Cowen P.J., Goodwin G.M. Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology 2002, 163:106-110.
156. Harper H.A. Biochemistry of serotonin. Diseases of the Colon and Rectum 1964, 7:83-86.
157. Harvey J.A. Serotonergic regulation of associative learning. Behavioural Brain Research 1996, 73:47-50.
158. 2A receptor in learning. Learning & Memory 2003, 10:355-362.
159. 2A receptor density and associative learning. Psychopharmacology 2004, 172:435-442.
160. 2A receptor binding in patients with mild cognitive impairment. Neurobiology of Aging 2008, 29:1830-1838.
161. 3 receptor antagonists. Scandinavian Journal of Rheumatology. Supplement 2004, 119:12-18.
162. Hendricksen M., Thomas A.J., Ferrier I.N., Ince P., O'Brien J.T. Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. The American Journal of Psychiatry 2004, 161:1096-1102.
163. Heneka M.T., Rodriguez J.J., Verkhratsky A. Neuroglia in neurodegeneration. Brain Research Reviews 2010, 63:189-211.
164. Hensler J.G. Serotonergic modulation of the limbic system. Neuroscience and Biobehavioral Reviews 2006, 30:203-214.
165. Herrera A.J., Machado A., Cano J. The influence of age on neurotransmitter turnover in the rat's superior colliculus. Neurobiology of Aging 1991, 12:289-294.
166. 4 receptor agonism in the five-choice serial reaction time task. Behavioural Brain Research 2008, 195:180-186.
167. Hirano H., Day J., Fibiger H.C. Serotonergic regulation of acetylcholine release in rat frontal cortex. Journal of Neurochemistry 1995, 65:1139-1145.
168. Hirst W.D., Andree T.H., Aschmies S., Childers W.E., Comery T.A., Dawson L.A., Day M., Feingold I.B., Grauer S.M., Harrison B.L., Hughes Z.A., Kao J., Kelly M.G., van der Lee H., Rosenzweig-Lipson S., Saab A.L., Smith D.L., Sullivan K., Rizzo S.J., Tio C., Zhang M.Y., Schechter L.E. Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexan e carboxamide (WAY-101405). The Journal of Pharmacology and Experimental Therapeutics 2008, 325:134-145.
169. 6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. European Journal of Pharmacology 2006, 553:109-119.
170. ΔE9 amyloid overexpressing mice. Journal of Alzheimer's Disease 2010, 20:1201-1213.
171. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacology, Biochemistry, and Behavior 2002, 71:533-554.
172. Hu M., Retz W., Baader M., Pesold B., Adler G., Henn F.A., Rosler M., Thome J. Promoter polymorphism of the 5-HT transporter and Alzheimer's disease. Neuroscience Letters 2000, 294:63-65.
173. Imeri L., De Simoni M.G., Giglio R., Clavenna A., Mancia M. Changes in the serotonergic system during the sleep-wake cycle: simultaneous polygraphic and voltammetric recordings in hypothalamus using a telemetry system. Neuroscience 1994, 58:353-358.
174. Ishii T. Distribution of Alzheimer's neurofibrillary changes in the brain stem and hypothalamus of senile dementia. Acta Neuropathologica 1966, 6:181-187.
175. 2 receptors in living human brain. Progress in Neuro-psychopharmacology & Biological Psychiatry 1993, 17:415-421.
176. Jacobs B.L., Azmitia E.C. Structure and function of the brain serotonin system. Physiological Reviews 1992, 72:165-229.
177. Jacobs B.L., Fornal C.A. Serotonin and motor activity. Current Opinion in Neurobiology 1997, 7:820-825.
178. 2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:735-740.
179. Jansen K.L., Faull R.L., Dragunow M., Synek B.L. Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors - an autoradiographic study. Neuroscience 1990, 39:613-627.
180. Jeltsch-David H., Koenig J., Cassel J.C. Modulation of cholinergic functions by serotonin and possible implications in memory: general data and focus on 5-HT(1A) receptors of the medial septum. Behavioural Brain Research 2008, 195:86-97.
181. 7 agonist 8-OH-DPAT and working memory in rats. Psychopharmacology 2004, 175:37-46.
182. Jones B.E. Immunohistochemical study of choline acetyltransferase-immunoreactive processes and cells innervating the pontomedullary reticular formation in the rat. The Journal of Comparative Neurology 1990, 295:485-514.
183. Jones B.E., Cuello A.C. Afferents to the basal forebrain cholinergic cell area from pontomesencephalic - catecholamine, serotonin, and acetylcholine - neurons. Neuroscience 1989, 31:37-61.
184. Kalaria R.N., Kenny R.A., Ballard C.G., Perry R., Ince P., Polvikoski T. Towards defining the neuropathological substrates of vascular dementia. Journal of the Neurological Sciences 2004, 226:75-80.
185. 1A receptor antagonist NAD-299 increases acetylcholine release but not extracellular glutamate levels in the frontal cortex and hippocampus of awake rat. European Neuropsychopharmacology 2010, 20:487-500.
186. Kepe V., Barrio J.R., Huang S.C., Ercoli L., Siddarth P., Shoghi-Jadid K., Cole G.M., Satyamurthy N., Cummings J.L., Small G.W., Phelps M.E. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:702-707.
187. Kern A., Behl C. The unsolved relationship of brain aging and late-onset Alzheimer disease. Biochimica et Biophysica Acta 2009, 1790:1124-1132.
188. Keuker J.I., Keijser J.N., Nyakas C., Luiten P.G., Fuchs E. Aging is accompanied by a subfield-specific reduction of serotonergic fibers in the tree shrew hippocampal formation. Journal of Chemical Neuroanatomy 2005, 30:221-229.
189. Khaliq S., Haider S., Ahmed S.P., Perveen T., Haleem D.J. Relationship of brain tryptophan and serotonin in improving cognitive performance in rats. Pakistan Journal of Pharmaceutical Sciences 2006, 19:11-15.
190. Kia H.K., Brisorgueil M.J., Daval G., Langlois X., Hamon M., Verge D. Serotonin1A receptors are expressed by a subpopulation of cholinergic neurons in the rat medial septum and diagonal band of Broca - a double immunocytochemical study. Neuroscience 1996, 74:143-154.
191. Kloppel S., Kovacs G.G., Voigtlander T., Wanschitz J., Flicker H., Hainfellner J.A., Guentchev M., Budka H. Serotonergic nuclei of the raphe are not affected in human ageing. Neuroreport 2001, 12:669-671.
192. Ko M.L., King M.A., Gordon T.L., Crisp T. The effects of aging on spinal neurochemistry in the rat. Brain Research Bulletin 1997, 42:95-98.
193. 1A receptors alters spatial memory encoding, interferes with consolidation, but does not affect retrieval in rats subjected to a water-maze task. Hippocampus 2008, 18:99-118.
194. 7 serotonin receptor mRNA expression with aging in rat brain. Brain Research. Molecular Brain Research 2000, 79:163-168.
195. Kohler C., Chan-Palay V., Steinbusch H. The distribution and origin of serotonin-containing fibers in the septal area: a combined immunohistochemical and fluorescent retrograde tracing study in the rat. The Journal of Comparative Neurology 1982, 209:91-111.
196. Kosofsky B.E., Molliver M.E. The serotoninergic innervation of cerebral cortex: different classes of axon terminals arise from dorsal and median raphe nuclei. Synapse 1987, 1:153-168.
197. Kovacs G.G., Kloppel S., Fischer I., Dorner S., Lindeck-Pozza E., Birner P., Botefur I.C., Pilz P., Volk B., Budka H. Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders. Neuroreport 2003, 14:73-76.
198. Kraepelin E. Psychiatrie: Ein Lehrbuch fuer Studierende und Arzte 1910, Johann Ambrosius Barth, Leipzig.
199. Kunugi H., Ueki A., Otsuka M., Isse K., Hirasawa H., Kato N., Nabika T., Kobayashi S., Nanko S. Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: no evidence for an association. American Journal of Medical Genetics. Part A 2000, 96:307-309.
200. Kwon M.O., Fischer F., Matthisson M., Herrling P. List of drugs in development for neurodegenerative diseases. Update June 2004. Neuro-degenerative Diseases 2004, 1:113-152.
201. 2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology 2005, 179:673-677.
202. Lai M.K., Tsang S.W., Esiri M.M., Francis P.T., Wong P.T., Chen C.P. Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease. Psychopharmacology 2011, 213:431-439.
203. 4 receptors in the postmortem neocortex of Alzheimer disease: a clinicopathological study. Journal of Neural Transmission 2003, 110:779-788.
204. 1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Research 2003, 974:82-87.
205. Lai M.K., Tsang S.W., Francis P.T., Keene J., Hope T., Esiri M.M., Spence I., Chen C.P. Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease. Neuroreport 2002, 13:1175-1178.
206. Lambe E.K., Aghajanian G.K. The role of Kv1.2-containing potassium channels in serotonin-induced glutamate release from thalamocortical terminals in rat frontal cortex. The Journal of Neuroscience 2001, 21:9955-9963.
207. Lanctot K.L., Herrmann N., Ganjavi H., Black S.E., Rusjan P.M., Houle S., Wilson A.A. Serotonin-1A receptors in frontotemporal dementia compared with controls. Psychiatry Research 2007, 156:247-250.
208. 3 receptors in the aged human spinal cord. Journal of Chemical Neuroanatomy 1996, 11:67-75.
209. Lehmann O., Jeltsch H., Lazarus C., Tritschler L., Bertrand F., Cassel J.C. Combined 192 IgG-saporin and 5,7-dihydroxytryptamine lesions in the male rat brain: a neurochemical and behavioral study. Pharmacology, Biochemistry, and Behavior 2002, 72:899-912.
210. Lehmann O., Jeltsch H., Lehnardt O., Pain L., Lazarus C., Cassel J.C. Combined lesions of cholinergic and serotonergic neurons in the rat brain using 192 IgG-saporin and 5,7-dihydroxytryptamine: neurochemical and behavioural characterization. The European Journal of Neuroscience 2000, 12:67-79.
211. 4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse. Naunyn-Schmiedeberg's Archives of Pharmacology 2003, 367:621-628.
212. Levkovitz Y., Richter-Levin G., Segal M. Effect of 5-hydroxytryptophane on behavior and hippocampal physiology in young and old rats. Neurobiology of Aging 1994, 15:635-641.
213. 4 receptor and the amyloid precursor protein processing. Experimental Gerontology 2003, 38:159-166.
214. Lieben C.K., Blokland A., Westerink B., Deutz N.E. Acute tryptophan and serotonin depletion using an optimized tryptophan-free protein-carbohydrate mixture in the adult rat. Neurochemistry International 2004, 44:9-16.
215. Liu C.K., Lai C.L., Tai C.T., Lin R.T., Yen Y.Y., Howng S.L. Incidence and subtypes of dementia in southern Taiwan: impact of socio-demographic factors. Neurology 1998, 50:1572-1579.
216. Liu J.P., Lauder J.M. S-100 β and insulin-like growth factor-II differentially regulate growth of developing serotonin and dopamine neurons in vitro. The Journal of Neuroscience Research 1992, 33:248-256.
217. Liu Y., Yoo M.J., Savonenko A., Stirling W., Price D.L., Borchelt D.R., Mamounas L., Lyons W.E., Blue M.E., Lee M.K. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. The Journal of Neuroscience 2008, 28:13805-13814.
218. 6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neuroscience 2006, 7:36.
219. Loubinoux I., Pariente J., Boulanouar K., Carel C., Manelfe C., Rascol O., Celsis P., Chollet F. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. NeuroImage 2002, 15:26-36.
220. Luellen B.A., Bianco L.E., Schneider L.M., Andrews A.M. Reduced brain-derived neurotrophic factor is associated with a loss of serotonergic innervation in the hippocampus of aging mice. Genes, Brain, and Behavior 2007, 6:482-490.
221. 1A receptors in spatial and aversive learning in the rat. Neuropharmacology 2005, 48:830-852.
222. Luttgen M., Ogren S.O., Meister B. 5-HT1A receptor mRNA and immunoreactivity in the rat medial septum/diagonal band of Broca-relationships to GABAergic and cholinergic neurons. Journal of Chemical Neuroanatomy 2005, 29:93-111.
223. Lyketsos C.G., DelCampo L., Steinberg M., Miles Q., Steele C.D., Munro C., Baker A.S., Sheppard J.M., Frangakis C., Brandt J., Rabins P.V. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Archives of General Psychiatry 2003, 60:737-746.
224. Lyketsos C.G., Olin J. Depression in Alzheimer's disease: overview and treatment. Biological Psychiatry 2002, 52:243-252.
225. Lyketsos C.G., Sheppard J.M., Steele C.D., Kopunek S., Steinberg M., Baker A.S., Brandt J., Rabins P.V. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. The American Journal of Psychiatry 2000, 157:1686-1689.
226. Lyness S.A., Zarow C., Chui H.C. Neuron loss in key cholinergic and minergic nuclei in Alzheimer disease: a meta-analysis. Neurobiology of Aging 2003, 24:1-23.
227. Machado A., Cano J., Santiago M. The change with age in biogenic amines and their metabolites in the striatum of the rat. Archives of Gerontology and Geriatrics 1986, 5:333-342.
228. Madjid N., Tottie E.E., Luttgen M., Meister B., Sandin J., Kuzmin A., Stiedl O., Ogren S.O. 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. The Journal of Pharmacology and Experimental Therapeutics 2006, 316:581-591.
229. Magai C., Kennedy G., Cohen C.I., Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. The American Journal of Geriatric Psychiatry 2000, 8:66-74.
230. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. The Journal of Neuroscience 2000, 20:9104-9110.
231. Mamounas L.A., Altar C.A., Blue M.E., Kaplan D.R., Tessarollo L., Lyons W.E. BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. The Journal of Neuroscience 2000, 20:771-782.
232. Marchetti E., Chaillan F.A., Dumuis A., Bockaert J., Soumireu-Mourat B., Roman F.S. Modulation of memory processes and cellular excitability in the dentate gyrus of freely moving rats by a 5-HT4 receptors partial agonist, and an antagonist. Neuropharmacology 2004, 47:1021-1035.
233. Marchetti E., Jacquet M., Jeltsch H., Migliorati M., Nivet E., Cassel J.C., Roman F.S. Complete recovery of olfactory associative learning by activation of 5-HT4 receptors after dentate granule cell damage in rats. Neurobiology of Learning and Memory 2008, 90:185-191.
234. Marcos B., Chuang T.T., Gil-Bea F.J., Ramirez M.J. Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. British Journal of Pharmacology 2008, 155:434-440.
235. Marcussen A.B., Flagstad P., Kristjansen P.E., Johansen F.F., Englund U. Increase in neurogenesis and behavioural benefit after chronic fluoxetine treatment in Wistar rats. Acta Neurologica Scandinavica 2008, 117:94-100.
236. Marcusson J., Oreland L., Winblad B. Effect of age on human brain serotonin (S-1) binding sites. Journal of Neurochemistry 1984, 43:1699-1705.
237. Marcusson J.O., Alafuzoff I., Backstrom I.T., Ericson E., Gottfries C.G., Winblad B. 5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders. Brain Research 1987, 425:137-145.
238. Marcusson J.O., Morgan D.G., Winblad B., Finch C.E. Serotonin-2 binding sites in human frontal cortex and hippocampus. Selective loss of S-2A sites with age. Brain Research 1984, 311:51-56.
239. Marcyniuk B., Mann D.M., Yates P.O. The topography of cell loss from locus caeruleus in Alzheimer's disease. Journal of the Neurological Sciences 1986, 76:335-345.
240. Marek G.J., Aghajanian G.K. 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. European Journal of Pharmacology 1999, 367:197-206.
241. Marksteiner J., Walch T., Bodner T., Gurka P., Donnemiller E. Fluoxetine in Alzheimer's disease with severe obsessive compulsive symptoms and a low density of serotonin transporter sites. Pharmacopsychiatry 2003, 36:207-209.
242. Marner L., Frokjaer V.G., Kalbitzer J., Lehel S., Madsen K., Baare W.F., Knudsen G.M., Hasselbalch S.G. Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study. Neurobiology of Aging 2010, 33:479-487.
243. Marner L., Gillings N., Madsen K., Erritzoe D., Baare W.F., Svarer C., Hasselbalch S.G., Knudsen G.M. Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. NeuroImage 2010, 50:855-861.
244. Martin-Cora F.J., Pazos A. Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species. British Journal of Pharmacology 2004, 141:92-104.
245. Masliah E., Mallory M., Hansen L., Alford M., Albright T., DeTeresa R., Terry R., Baudier J., Saitoh T. Patterns of aberrant sprouting in Alzheimer's disease. Neuron 1991, 6:729-739.
246. Mathews T.A., Fedele D.E., Coppelli F.M., Avila A.M., Murphy D.L., Andrews A.M. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. Journal of Neuroscience Methods 2004, 140:169-181.
247. Mazer C., Muneyyirci J., Taheny K., Raio N., Borella A., Whitaker-Azmitia P. Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat: a possible model of neurodevelopmental disorders with cognitive deficits. Brain Research 1997, 760:68-73.
248. Meister B., Johnson H., Ulfhake B. Increased expression of serotonin transporter messenger RNA in raphe neurons of the aged rat. Brain Research. Molecular Brain Research 1995, 33:87-96.
249. Meltzer C.C., Price J.C., Mathis C.A., Greer P.J., Cantwell M.N., Houck P.R., Mulsant B.H., Ben-Eliezer D., Lopresti B., DeKosky S.T., Reynolds C.F. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. The American Journal of Psychiatry 1999, 156:1871-1878.
250. Meltzer C.C., Smith G., DeKosky S.T., Pollock B.G., Mathis C.A., Moore R.Y., Kupfer D.J., Reynolds C.F. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998, 18:407-430.
251. Meltzer C.C., Smith G., Price J.C., Reynolds C.F., Mathis C.A., Greer P., Lopresti B., Mintun M.A., Pollock B.G., Ben-Eliezer D., Cantwell M.N., Kaye W., DeKosky S.T. Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Research 1998, 813:167-171.
252. Meneses A. 5-HT system and cognition. Neuroscience and Biobehavioral Reviews 1999, 23:1111-1125.
253. Meneses A. Involvement of 5-HT(2A/2B/2C) receptors on memory formation: simple agonism, antagonism, or inverse agonism?. Cellular and Molecular Neurobiology 2002, 22:675-688.
254. Meneses A., Hong E. A pharmacological analysis of serotonergic receptors: effects of their activation of blockade in learning. Progress in Neuro-psychopharmacology & Biological Psychiatry 1997, 21:273-296.
255. Meneses A., Hong E. Role of 5-HT1B, 5-HT2A and 5-HT2C receptors in learning. Behavioural Brain Research 1997, 87:105-110.
256. Meneses A., Manuel-Apolinar L., Castillo C., Castillo E. Memory consolidation and amnesia modify 5-HT6 receptors expression in rat brain: an autoradiographic study. Behavioural Brain Research 2007, 178:53-61.
257. Meneses A., Perez-Garcia G. 5-HT(1A) receptors and memory. Neuroscience and Biobehavioral Reviews 2007, 31:705-727.
258. Meneses A., Perez-Garcia G., Liy-Salmeron G., Flores-Galvez D., Castillo C., Castillo E. The effects of the 5-HT(6) receptor agonist EMD and the 5-HT(7) receptor agonist AS19 on memory formation. Behavioural Brain Research 2008, 195:112-119.
259. Merens W., Booij L., Haffmans P.J., van der Does A. The effects of experimentally lowered serotonin function on emotional information processing and memory in remitted depressed patients. Journal of Psychopharmacology 2008, 22:653-662.
260. Mesulam M., Shaw P., Mash D., Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Annals of Neurology 2004, 55:815-828.
261. Mesulam M.M., Mufson E.J., Levey A.I., Wainer B.H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. The Journal of Comparative Neurology 1983, 214:170-197.
262. Micale V., Leggio G.M., Mazzola C., Drago F. Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia. Brain Research 2006, 1121:207-215.
263. Michelsen K.A., Prickaerts J., Steinbusch H.W. The dorsal raphe nucleus and serotonin: implications for neuroplasticity linked to major depression and Alzheimer's disease. Progress in Brain Research 2008, 172:233-264.
264. Michelsen K.A., Schmitz C., Steinbusch H.W. The dorsal raphe nucleus - from silver stainings to a role in depression. Brain Research Reviews 2007, 55:329-342.
265. Middlemiss D.N., Palmer A.M., Edel N., Bowen D.M. Binding of the novel serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin in normal and Alzheimer brain. Journal of Neurochemistry 1986, 46:993-996.
266. Miguel-Hidalgo J.J., Alvarez X.A., Cacabelos R., Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Research 2002, 958:210-221.
267. Miguez J.M., Aldegunde M., Paz-Valinas L., Recio J., Sanchez-Barcelo E. Selective changes in the contents of noradrenaline, dopamine and serotonin in rat brain areas during aging. Journal of Neural Transmission 1999, 106:1089-1098.
268. Millan M.J. Descending control of pain. Progress in Neurobiology 2002, 66:355-474.
269. Millan M.J., Gobert A., Roux S., Porsolt R., Meneses A., Carli M., Di Cara B., Jaffard R., Rivet J.M., Lestage P., Mocaer E., Peglion J.L., Dekeyne A. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis. The Journal of Pharmacology and Experimental Therapeutics 2004, 311:190-203.
270. Milner T.A., Veznedaroglu E. Serotonin-containing terminals synapse on septohippocampal neurons in the rat. The Journal of Neuroscience Research 1993, 36:260-271.
271. Mimica N., Muck-Seler D., Pivac N., Mustapic M., Dezeljin M., Stipcevic T., Presecki P., Radonic E., Folnegovic-Smalc V. Platelet serotonin and monoamine oxidase in Alzheimer's disease with psychotic features. Collegium Antropologicum 2008, 32(Suppl. 1):119-122.
272. Misane I., Ogren S.O. Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology 2003, 28:253-264.
273. Mitchell E.S., Sexton T., Neumaier J.F. Increased expression of 5-HT6 receptors in the rat dorsomedial striatum impairs instrumental learning. Neuropsychopharmacology 2007, 32:1520-1530.
274. Mizoguchi K., Tanaka Y., Tabira T. Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex. Journal of Ethnopharmacology 2010, 127:70-76.
275. Mizukami K., Hatanaka K., Tanaka Y., Sato S., Asada T. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease. Progress in Neuro-psychopharmacology & Biological Psychiatry 2009, 33:349-352.
276. Mizukami K., Ishikawa M., Akatsu H., Abrahamson E.E., Ikonomovic M.D., Asada T. An immunohistochemical study of the serotonin 1A receptor in the hippocampus of subjects with Alzheimer's disease. Neuropathology 2011, 31:503-509.
277. 4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacology 2007, 53:563-573.
278. Mohs R.C. The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials. Genes, Brain, and Behavior 2005, 4:129-133.
279. Molliver M.E. Serotonergic neuronal systems: what their anatomic organization tells us about function. Journal of Clinical Psychopharmacology 1987, 7:3S-23S.
280. Monaco F., Fumero S., Mondino A., Mutani R. Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases. Journal of Neurology, Neurosurgery, and Psychiatry 1979, 42:640-641.
281. Morales M., Battenberg E., de Lecea L., Sanna P.P., Bloom F.E. Cellular and subcellular immunolocalization of the type 3 serotonin receptor in the rat central nervous system. Brain Research. Molecular Brain Research 1996, 36:251-260.
282. Morales M., Bloom F.E. The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. The Journal of Neuroscience 1997, 17:3157-3167.
283. Morgan M.J. Memory deficits associated with recreational use of ecstasy (MDMA). Psychopharmacology 1999, 141:30-36.
284. Morse L.J., Payton S.M., Cuny G.D., Rogers J.T. FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. Journal of Molecular Neuroscience 2004, 24:129-136.
285. Moser P.C., Bergis O.E., Jegham S., Lochead A., Duconseille E., Terranova J.P., Caille D., Berque-Bestel I., Lezoualc'h F., Fischmeister R., Dumuis A., Bockaert J., George P., Soubrie P., Scatton B. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. The Journal of Pharmacology and Experimental Therapeutics 2002, 302:731-741.
286. Mossello E., Boncinelli M., Caleri V., Cavallini M.C., Palermo E., Di Bari M., Tilli S., Sarcone E., Simoni D., Biagini C.A., Masotti G., Marchionni N. Is antidepressant treatment associated with reduced cognitive decline in Alzheimer's disease?. Dementia and Geriatric Cognition Disorders 2008, 25:372-379.
287. Mowla A., Mosavinasab M., Haghshenas H., Borhani Haghighi A. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. Journal of Clinical Psychopharmacology 2007, 27:484-487.
288. Muck-Seler D., Presecki P., Mimica N., Mustapic M., Pivac N., Babic A., Nedic G., Folnegovic-Smalc V. Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease. Progress in Neuro-psychopharmacology & Biological Psychiatry 2009, 33:1226-1231.
289. Muller C., Jacobs B. Handbook of the Behavioral Neurobiology of Serotonin 2009, Elsevier.
290. Munro C.A., Brandt J., Sheppard J.M., Steele C.D., Samus Q.M., Steinberg M., Rabins P.V., Lyketsos C.G. Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer's disease study (DIADS). The American Journal of Geriatric Psychiatry 2004, 12:491-498.
291. Navarro H.A., Aloyo V.J., Rush M.E., Walker R.F. Serotonin pharmacodynamics in hypothalamic tissues from young and old female rats. Brain Research 1987, 421:291-296.
292. Nazarali A.J., Reynolds G.P. Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. Cellular and Molecular Neurobiology 1992, 12:581-587.
293. Nelson R.L., Guo Z., Halagappa V.M., Pearson M., Gray A.J., Matsuoka Y., Brown M., Martin B., Iyun T., Maudsley S., Clark R.F., Mattson M.P. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Experimental Neurology 2007, 205:166-176.
294. Newhouse P., Tatro A., Naylor M., Quealey K., Delgado P. Alzheimer disease, serotonin systems, and tryptophan depletion. The American Journal of Geriatric Psychiatry 2002, 10:483-484.
295. Niesler B., Kapeller J., Hammer C., Rappold G. Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics 2008, 9:501-504.
296. Nilsson O.G., Brundin P., Bjorklund A. Amelioration of spatial memory impairment by intrahippocampal grafts of mixed septal and raphe tissue in rats with combined cholinergic and serotonergic denervation of the forebrain. Brain Research 1990, 515:193-206.
297. Nilsson O.G., Strecker R.E., Daszuta A., Bjorklund A. Combined cholinergic and serotonergic denervation of the forebrain produces severe deficits in a spatial learning task in the rat. Brain Research 1988, 453:235-246.
298. Nishimura A., Ueda S., Takeuchi Y., Matsushita H., Sawada T., Kawata M. Vulnerability to aging in the rat serotonergic system. Acta Neuropathologica 1998, 96:581-595.
299. Nishimura A., Ueda S., Takeuchi Y., Sawada T., Kawata M. Age-related decrease of serotonergic fibres and S-100 beta immunoreactivity in the rat dentate gyrus. Neuroreport 1995, 6:1445-1448.
300. Nitsch R.M., Deng M., Growdon J.H., Wurtman R.J. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. The Journal of Biological Chemistry 1996, 271:4188-4194.
301. Nomura M. Effects of bifemelane on discrimination learning of serotonergic-dysfunction rats. Pharmacology, Biochemistry, and Behavior 1992, 42:721-731.
302. Noristani H.N., Meadows R.S., Olabarria M., Verkhratsky A., Rodríguez J.J. Increased hippocampal CA1 density of serotonergic terminals in a triple transgenic mouse model of Alzheimer's disease: an ultrastructural study. Cell Death & Disease 2011, 2:e210.
303. Noristani H.N., Olabarria M., Verkhratsky A., Rodriguez J.J. Serotonin fibre sprouting and increase in serotonin transporter immunoreactivity in the CA1 area of hippocampus in a triple transgenic mouse model of Alzheimer's disease. The European Journal of Neuroscience 2010, 32:71-79.
304. Nyth A.L., Gottfries C.G. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. The British Journal of Psychiatry: the Journal of Mental Science 1990, 157:894-901.
305. Nyth A.L., Gottfries C.G., Lyby K., Smedegaard-Andersen L., Gylding-Sabroe J., Kristensen M., Refsum H.E., Ofsti E., Eriksson S., Syversen S. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatrica Scandinavica 1992, 86:138-145.
306. O'Hearn E., Battaglia G., De Souza E.B., Kuhar M.J., Molliver M.E. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. The Journal of Neuroscience 1988, 8:2788-2803.
307. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiology of Aging 2003, 24:1063-1070.
308. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
309. Ohsugi K., Adachi K., Mukoyama M., Ando K. Lack of change in indoleamine metabolism in spinal cord of patients with amyotrophic lateral sclerosis. Neuroscience Letters 1987, 79:351-354.
310. Olabarria M., Noristani H.N., Verkhratsky A., Rodriguez J.J. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia 2010, 58:831-838.
311. Olvera-Cortes M.E., Anguiano-Rodriguez P., Lopez-Vazquez M.A., Alfaro J.M. Serotonin/dopamine interaction in learning. Progress in Brain Research 2008, 172:567-602.
312. Orsetti M., Dellarole A., Ferri S., Ghi P. Acquisition, retention, and recall of memory after injection of RS67333, a 5-HT(4) receptor agonist, into the nucleus basalis magnocellularis of the rat. Learning & Memory 2003, 10:420-426.
313. Ott A., Breteler M.M., van Harskamp F., Claus J.J., van der Cammen T.J., Grobbee D.E., Hofman A. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995, 310:970-973.
314. Ouchi Y., Yoshikawa E., Futatsubashi M., Yagi S., Ueki T., Nakamura K. Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease. Journal of Nuclear Medicine 2009, 50:1260-1266.
315. Owen F., Chambers D.R., Cooper S.J., Crow T.J., Johnson J.A., Lofthouse R., Poulter M. Serotonergic mechanisms in brains of suicide victims. Brain Research 1986, 362:185-188.
316. Pakaski M., Bjelik A., Hugyecz M., Kasa P., Janka Z., Kalman J. Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochemistry International 2005, 47:190-195.
317. Palmer A.M., DeKosky S.T. Monoamine neurons in aging and Alzheimer's disease. Journal of Neural Transmission. General Section 1993, 91:135-159.
318. Palmer A.M., Francis P.T., Benton J.S., Sims N.R., Mann D.M., Neary D., Snowden J.S., Bowen D.M. Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. Journal of Neurochemistry 1987, 48:8-15.
319. Parsey R.V., Oquendo M.A., Simpson N.R., Ogden R.T., Van Heertum R., Arango V., Mann J.J. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Research 2002, 954:173-182.
320. Parsons M.J., Benca R.M., Brownfield M.S., Behan M. Age-associated changes in the serotonergic system in rat superior colliculus and pretectum. Brain Research Bulletin 2001, 55:435-444.
321. Pasik T., Pasik P. Texture of the Nervous System of Man and the Vertebrates 2000, Springer, New York.
322. Patel T.D., Zhou F.C. Ontogeny of 5-HT1A receptor expression in the developing hippocampus. Brain Research Development. Brain Research 2005, 157:42-57.
323. Payton S., Cahill C.M., Randall J.D., Gullans S.R., Rogers J.T. Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol. Journal of Molecular Neuroscience 2003, 20:267-275.
324. Peddie C.J., Davies H.A., Colyer F.M., Stewart M.G., Rodríguez J.J. Colocalisation of serotonin2A receptors with the glutamate receptor subunits NR1 and GluR2 in the dentate gyrus: an ultrastructural study of a modulatory role. Experimental Neurology 2008, 211:561-573.
325. Peddie C.J., Davies H.A., Colyer F.M., Stewart M.G., Rodriguez J.J. Dendritic colocalisation of serotonin1B receptors and the glutamate NMDA receptor subunit NR1 within the hippocampal dentate gyrus: an ultrastructural study. Journal of Chemical Neuroanatomy 2008, 36:17-26.
326. Perez-Garcia G., Gonzalez-Espinosa C., Meneses A. An mRNA expression analysis of stimulation and blockade of 5-HT7 receptors during memory consolidation. Behavioural Brain Research 2006, 169:83-92.
327. Perez-Garcia G., Meneses A. Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacology, Biochemistry, and Behavior 2005, 81:673-682.
328. Peroutka S.J., Lebovitz R.M., Snyder S.H. Two distinct central serotonin receptors with different physiological functions. Science 1981, 212:827-829.
329. Perry E.K., Perry R.H., Candy J.M., Fairbairn A.F., Blessed G., Dick D.J., Tomlinson B.E. Cortical serotonin-S2 receptor binding abnormalities in patients with Alzheimer's disease: comparisons with Parkinson's disease. Neuroscience Letters 1984, 51:353-357.
330. Petkov V.D., Stancheva S.L., Petkov V.V., Alova L.G. Age-related changes in brain biogenic monoamines and monoamine oxidase. General Pharmacology 1987, 18:397-401.
331. Petracca G., Teson A., Chemerinski E., Leiguarda R., Starkstein S.E. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. The Journal of Neuropsychiatry and Clinical Neurosciences 1996, 8:270-275.
332. Petracca G.M., Chemerinski E., Starkstein S.E. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. International Psychogeriatrics 2001, 13:233-240.
333. Phinney A.L., Deller T., Stalder M., Calhoun M.E., Frotscher M., Sommer B., Staufenbiel M., Jucker M. Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. The Journal of Neuroscience 1999, 19:8552-8559.
334. Pirker W., Asenbaum S., Hauk M., Kandlhofer S., Tauscher J., Willeit M., Neumeister A., Praschak-Rieder N., Angelberger P., Brucke T. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. Journal of Nuclear Medicine 2000, 41:36-44.
335. Pitsikas N., Borsini F. Itasetron (DAU 6215) prevents age-related memory deficits in the rat in a multiple choice avoidance task. European Journal of Pharmacology 1996, 311:115-119.
336. Pitsikas N., Borsini F. Different effects of tropisetron and ondansetron in learning and memory paradigms. Pharmacology, Biochemistry, and Behavior 1997, 56:571-576.
337. Pitsikas N., Tsitsirigou S., Zisopoulou S., Sakellaridis N. The 5-HT1A receptor and recognition memory. Possible modulation of its behavioral effects by the nitrergic system. Behavioural Brain Research 2005, 159:287-293.
338. Pollock B.G., Mulsant B.H., Rosen J., Sweet R.A., Mazumdar S., Bharucha A., Marin R., Jacob N.J., Huber K.A., Kastango K.B., Chew M.L. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. The American Journal of Psychiatry 2002, 159:460-465.
339. Ponzio F., Calderini G., Lomuscio G., Vantini G., Toffano G., Algeri S. Changes in monoamines and their metabolite levels in some brain regions of aged rats. Neurobiology of Aging 1982, 3:23-29.
340. Porter R.J., Lunn B.S., O'Brien J.T. Effects of acute tryptophan depletion on cognitive function in Alzheimer's disease and in the healthy elderly. Psychological Medicine 2003, 33:41-49.
341. Porter R.J., Lunn B.S., Walker L.L., Gray J.M., Ballard C.G., O'Brien J.T. Cognitive deficit induced by acute tryptophan depletion in patients with Alzheimer's disease. The American Journal of Psychiatry 2000, 157:638-640.
342. Procter A.W., Lowe S.L., Palmer A.M., Francis P.T., Esiri M.M., Stratmann G.C., Najlerahim A., Patel A.J., Hunt A., Bowen D.M. Topographical distribution of neurochemical changes in Alzheimer's disease. Journal of the Neurological Sciences 1988, 84:125-140.
343. Pucadyil T.J., Kalipatnapu S., Chattopadhyay A. The serotonin1A receptor: a representative member of the serotonin receptor family. Cellular and Molecular Neurobiology 2005, 25:553-580.
344. Puig M.V., Santana N., Celada P., Mengod G., Artigas F. In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cerebral Cortex 2004, 14:1365-1375.
345. Qiu C., Kivipelto M., von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues in Clinical Neuroscience 2009, 11:111-128.
346. Rada P.V., Mark G.P., Hoebel B.G. In vivo modulation of acetylcholine in the nucleus accumbens of freely moving rats: I. Inhibition by serotonin. Brain Research 1993, 619:98-104.
347. Raina P., Santaguida P., Ismaila A., Patterson C., Cowan D., Levine M., Booker L., Oremus M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Annals of Internal Medicine 2008, 148:379-397.
348. Ramirez M.J., Cenarruzabeitia E., Lasheras B., Del Rio J. Involvement of GABA systems in acetylcholine release induced by 5-HT3 receptor blockade in slices from rat entorhinal cortex. Brain Research 1996, 712:274-280.
349. Ramón y Cajal S. Textura del Sistema Nervioso del Hombre y los Vertebrados 1904.
350. Rao V., Spiro J.R., Rosenberg P.B., Lee H.B., Rosenblatt A., Lyketsos C.G. An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD). International Journal of Geriatric Psychiatry 2006, 21:273-274.
351. Rapport M.M. Serum vasoconstrictor (serotonin) the presence of creatinine in the complex; a proposed structure of the vasoconstrictor principle. The Journal of Biological Chemistry 1949, 180:961-969.
352. Rapport M.M., Green A.A., Page I.H. Serum vasoconstrictor, serotonin; chemical inactivation. The Journal of Biological Chemistry 1948, 176:1237-1241.
353. Rapport M.M., Green A.A., Page I.H. Serum vasoconstrictor, serotonin; isolation and characterization. The Journal of Biological Chemistry 1948, 176:1243-1251.
354. Restivo L., Roman F., Dumuis A., Bockaert J., Marchetti E., Ammassari-Teule M. The promnesic effect of G-protein-coupled 5-HT4 receptors activation is mediated by a potentiation of learning-induced spine growth in the mouse hippocampus. Neuropsychopharmacology 2008, 33:2427-2434.
355. Reynolds G.P., Mason S.L., Meldrum A., De Keczer S., Parnes H., Eglen R.M., Wong E.H. 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. British Journal of Pharmacology 1995, 114:993-998.
356. Reznic J., Staubli U. Effects of 5-HT3 receptor antagonism on hippocampal cellular activity in the freely moving rat. Journal of Neurophysiology 1997, 77:517-521.
357. Richter-Levin G., Acsady L., Freund T.F., Segal M. Differential effects of serotonin and raphe grafts in the hippocampus and hypothalamus: a combined behavioural and anatomical study in the rat. The European Journal of Neuroscience 1994, 6:1720-1728.
358. Richter-Levin G., Greenberger V., Segal M. Regional specificity of raphe graft-induced recovery of behavioral functions impaired by combined serotonergic/cholinergic lesions. Experimental Neurology 1993, 121:256-260.
359. Richter-Levin G., Segal M. Spatial performance is severely impaired in rats with combined reduction of serotonergic and cholinergic transmission. Brain Research 1989, 477:404-407.
360. Richter-Levin G., Segal M. The effects of serotonin depletion and raphe grafts on hippocampal electrophysiology and behavior. The Journal of Neuroscience 1991, 11:1585-1596.
361. Richter-Levin G., Segal M. Restoration of serotonergic innervation underlies the behavioral effects of raphe grafts. Brain Research 1991, 566:21-25.
362. Richter-Levin G., Segal M. Raphe grafts in the hippocampus, but not in the entorhinal cortex, reverse hippocampal hyperexcitability of serotonin-depleted rats and restore their responsiveness to fenfluramine. Developmental Neuroscience 1992, 14:166-172.
363. Richter-Levin G., Segal M. Serotonin, aging and cognitive functions of the hippocampus. Reviews in the Neurosciences 1996, 7:103-113.
364. Riedel W.J., Klaassen T., Deutz N.E., van Someren A., van Praag H.M. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology 1999, 141:362-369.
365. Riekkinen P., Sirvio J., Valjakka A., Miettinen R., Riekkinen P. Pharmacological consequences of cholinergic plus serotonergic manipulations. Brain Research 1991, 552:23-26.
366. Robert S.J., Zugaza J.L., Fischmeister R., Gardier A.M., Lezoualc'h F. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. The Journal of Biological Chemistry 2001, 276:44881-44888.
367. Roberts A.J., Krucker T., Levy C.L., Slanina K.A., Sutcliffe J.G., Hedlund P.B. Mice lacking 5-HT receptors show specific impairments in contextual learning. The European Journal of Neuroscience 2004, 19:1913-1922.
368. Rocca P., Calvarese P., Faggiano F., Marchiaro L., Mathis F., Rivoira E., Taricco B., Bogetto F. Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial. The Journal of Clinical Psychiatry 2005, 66:360-369.
369. Rodriguez-Gomez J.A., de la Roza C., Machado A., Cano J. The effect of age on the monoamines of the hypothalamus. Mechanisms of Ageing and Development 1995, 77:185-195.
370. Rodríguez J.J., Noristani H.N., Hoover W.B., Linley S.B., Vertes R.P. Serotonergic projections and serotonin receptor expression in the reticular nucleus of the thalamus in the rat. Synapse 2011, 65:919-928.
371. Rodriguez J.J., Jones V.C., Tabuchi M., Allan S.M., Knight E.M., LaFerla F.M., Oddo S., Verkhratsky A. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One 2008, 3:e2935.
372. Rodriguez J.J., Jones V.C., Verkhratsky A. Impaired cell proliferation in the subventricular zone in an Alzheimer's disease model. Neuroreport 2009, 20:907-912.
373. Rodríguez J.J., Olabarria M., Chvatal A., Verkhratsky A. Astroglia in dementia and Alzheimer's disease. Cell Death and Differentiation 2009, 16:378-385.
374. Rodríguez J.J., Verkhratsky A. Neurogenesis in Alzheimer's disease. Journal of Anatomy 2011, 219:78-89.
375. Rodríguez J.J., Verkhratsky A. Neuroglial roots of neurodegenerative diseases?. Molecular Neurobiology 2011, 43:87-96.
376. Rogers D.C., Hagan J.J. 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology 2001, 158:114-119.
377. Romano A.G., Quinn J.L., Li L., Dave K.D., Schindler E.A., Aloyo V.J., Harvey J.A. Intrahippocampal LSD accelerates learning and desensitizes the 5-HT(2A) receptor in the rabbit, Romano et al. Psychopharmacology 2010, 212:441-448.
378. Rosier A., Dupont P., Peuskens J., Bormans G., Vandenberghe R., Maes M., de Groot T., Schiepers C., Verbruggen A., Mortelmans L. Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Research 1996, 68:11-22.
379. Roth M., Mountjoy C.Q., Amrein R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. The British Journal of Psychiatry: the Journal of Mental Science 1996, 168:149-157.
380. Rousset O.G., Ma Y., Evans A.C. Correction for partial volume effects in PET: principle and validation. Journal of Nuclear Medicine 1998, 39:904-911.
381. Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. The New England Journal of Medicine 2001, 344:1688-1700.
382. Rozzini L., Chilovi B.V., Conti M., Bertoletti E., Zanetti M., Trabucchi M., Padovani A. Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors. International Psychogeriatrics 2010, 22:114-119.
383. Rub U., Del Tredici K., Schultz C., Thal D.R., Braak E., Braak H. The evolution of Alzheimer's disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathology and Applied Neurobiology 2000, 26:553-567.
384. Rubinsztein J.S., Rogers R.D., Riedel W.J., Mehta M.A., Robbins T.W., Sahakian B.J. Acute dietary tryptophan depletion impairs maintenance of affective set and delayed visual recognition in healthy volunteers. Psychopharmacology 2001, 154:319-326.
385. Russo O., Cachard-Chastel M., Riviere C., Giner M., Soulier J.L., Berthouze M., Richard T., Monti J.P., Sicsic S., Lezoualc'h F., Berque-Bestel I. Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease. Journal of Medicinal Chemistry 2009, 52:2214-2225.
386. Sambeth A., Blokland A., Harmer C.J., Kilkens T.O., Nathan P.J., Porter R.J., Schmitt J.A., Scholtissen B., Sobczak S., Young A.H., Riedel W.J. Sex differences in the effect of acute tryptophan depletion on declarative episodic memory: a pooled analysis of nine studies. Neuroscience and Biobehavioral Reviews 2007, 31:516-529.
387. Sambeth A., Riedel W.J., Tillie D.E., Blokland A., Postma A., Schmitt J.A. Memory impairments in humans after acute tryptophan depletion using a novel gelatin-based protein drink. Journal of Psychopharmacology 2009, 23:56-64.
388. Sandyk R. Serotonergic mechanisms in amyotrophic lateral sclerosis. The International Journal of Neuroscience 2006, 116:775-826.
389. 2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cerebral Cortex 2004, 14:1100-1109.
390. 2A receptors in Alzheimer's disease with [(18)F]deuteroaltanserin and PET. Psychiatry Research 2009, 173:212-217.
391. Sarkisyan G., Hedlund P.B. The 5-HT7 receptor is involved in allocentric spatial memory information processing. Behavioural Brain Research 2009, 202:26-31.
392. Sarnyai Z., Sibille E.L., Pavlides C., Fenster R.J., McEwen B.S., Toth M. Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:14731-14736.
393. Schechter L.E., Smith D.L., Rosenzweig-Lipson S., Sukoff S.J., Dawson L.A., Marquis K., Jones D., Piesla M., Andree T., Nawoschik S., Harder J.A., Womack M.D., Buccafusco J., Terry A.V., Hoebel B., Rada P., Kelly M., Abou-Gharbia M., Barrett J.E., Childers W. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. The Journal of Pharmacology and Experimental Therapeutics 2005, 314:1274-1289.
394. Scheff S.W., Price D.A., Schmitt F.A., Mufson E.J. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging 2006, 27:1372-1384.
395. Scheibel A.B., Tomiyasu U. Dendritic sprouting in Alzheimer's presenile dementia. Experimental Neurology 1978, 60:1-8.
396. Schiapparelli L., Del Rio J., Frechilla D. Serotonin 5-HT receptor blockade enhances Ca(2+)/calmodulin-dependent protein kinase II function and membrane expression of AMPA receptor subunits in the rat hippocampus: implications for memory formation. Journal of Neurochemistry 2005, 94:884-895.
397. Schiapparelli L., Simon A.M., Del Rio J., Frechilla D. Opposing effects of AMPA and 5-HT1A receptor blockade on passive avoidance and object recognition performance: correlation with AMPA receptor subunit expression in rat hippocampus. Neuropharmacology 2006, 50:897-907.
398. Schmitt J.A., Jorissen B.L., Sobczak S., van Boxtel M.P., Hogervorst E., Deutz N.E., Riedel W.J. Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. Journal of Psychopharmacology 2000, 14:21-29.
399. Schmitz D., Gloveli T., Empson R.M., Heinemann U. Comparison of the effects of serotonin in the hippocampus and the entorhinal cortex. Molecular Neurobiology 1998, 17:59-72.
400. Schneider L.S., Pollock V.E., Zemansky M.F., Gleason R.P., Palmer R., Sloane R.B. A pilot study of low-dose L-deprenyl in Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology 1991, 4:143-148.
401. Scholtissen B., Verhey F.R., Adam J.J., Prickaerts J., Leentjens A.F. Effects of acute tryptophan depletion on cognition, memory and motor performance in Parkinson's disease. Journal of the Neurological Sciences 2006, 248:259-265.
402. Scruggs J.L., Schmidt D., Deutch A.Y. The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats. Neuroscience Letters 2003, 346:137-140.
403. Segu L., Lecomte M.J., Wolff M., Santamaria J., Hen R., Dumuis A., Berrard S., Bockaert J., Buhot M.C., Compan V. Hyperfunction of muscarinic receptor maintains long-term memory in 5-HT4 receptor knock-out mice. PLoS One 2010, 5:e9529.
404. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
405. Semba K., Reiner P.B., McGeer E.G., Fibiger H.C. Brainstem afferents to the magnocellular basal forebrain studied by axonal transport, immunohistochemistry, and electrophysiology in the rat. The Journal of Comparative Neurology 1988, 267:433-453.
406. Senut M.C., Menetrey D., Lamour Y. Cholinergic and peptidergic projections from the medial septum and the nucleus of the diagonal band of Broca to dorsal hippocampus, cingulate cortex and olfactory bulb: a combined wheatgerm agglutinin-apohorseradish peroxidase-gold immunohistochemical study. Neuroscience 1989, 30:385-403.
407. Seripa D., Franceschi M., D'Onofrio G., Panza F., Cascavilla L., Paris F., Placentino G., Matera M.G., Solfrizzi V., Pilotto A. Polymorphism C in the serotonin transporter gene (SLC6A4) in questionable dementia and Alzheimer's disease. Neuroscience Letters 2008, 438:335-339.
408. Severson J.A., Marcusson J.O., Osterburg H.H., Finch C.E., Winblad B. Elevated density of [3H]imipramine binding in aged human brain. Journal of Neurochemistry 1985, 45:1382-1389.
409. Shapiro L.A., Bialowas-McGoey L.A., Whitaker-Azmitia P.M. Effects of S100B on serotonergic plasticity and neuroinflammation in the hippocampus in down syndrome and Alzheimer's disease: Studies in an S100B overexpressing mouse model. Cardiovascular Psychiatry and Neurology 2010, 2010:1-13.
410. Shastry B.S., Giblin F.J. Genes and susceptible loci of Alzheimer's disease. Brain Research Bulletin 1999, 48:121-127.
411. Siddique H., Hynan L.S., Weiner M.F. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. The Journal of Clinical Psychiatry 2009, 70:915-918.
412. Simpkins J.W. Regional changes in monoamine metabolism in the aging constant estrous rat. Neurobiology of Aging 1984, 5:309-313.
413. Sirvio J., Riekkinen P., Jakala P., Riekkinen P.J. Experimental studies on the role of serotonin in cognition. Progress in Neurobiology 1994, 43:363-379.
414. Smith G.S., Kramer E., Ma Y., Hermann C.R., Dhawan V., Chaly T., Eidelberg D. Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain 2009, 132:392-401.
415. Sofic E., Riederer P., Gsell W., Gavranovic M., Schmidtke A., Jellinger K. Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 1991, 3:133-142.
416. Staubli U., Xu F.B. Effects of 5-HT3 receptor antagonism on hippocampal theta rhythm, memory, and LTP induction in the freely moving rat. The Journal of Neuroscience 1995, 15:2445-2452.
417. Steckler T., Sahgal A. The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behavioural Brain Research 1995, 67:165-199.
418. Steinbusch H.W. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 1981, 6:557-618.
419. Steinbusch H.W., Nieuwenhuys R., Verhofstad A.A., Van der Kooy D. The nucleus raphe dorsalis of the rat and its projection upon the caudatoputamen. A combined cytoarchitectonic, immunohistochemical and retrograde transport study. Journal of Physiology, Paris 1981, 77:157-174.
420. Steinbusch H.W., Van Luijtelaar M.G., Dijkstra H., Nijssen A., Tonnaer J.A. Aging and regenerative capacity of the rat serotonergic system. A morphological, neurochemical and behavioral analysis after transplantation of fetal raphe cells. Annals of the New York Academy of Sciences 1990, 600:384-402. discussion 402-384.
421. Stemmelin J., Lazarus C., Cassel S., Kelche C., Cassel J.C. Immunohistochemical and neurochemical correlates of learning deficits in aged rats. Neuroscience 2000, 96:275-289.
422. Stutzmann G.E. The pathogenesis of Alzheimers disease is it a lifelong calciumopathy?. Neuroscientist 2007, 13:546-559.
423. Sukonick D.L., Pollock B.G., Sweet R.A., Mulsant B.H., Rosen J., Klunk W.E., Kastango K.B., DeKosky S.T., Ferrell R.E. The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease. Archives of Neurology 2001, 58:1425-1428.
424. Supnet C., Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 2010, 47:183-189.
425. Takahashi M., Freed R., Blackmer T., Alford S. Calcium influx-independent depression of transmitter release by 5-HT at lamprey spinal cord synapses. The Journal of Physiology 2001, 532:323-336.
426. Takeda A., Loveman E., Clegg A., Kirby J., Picot J., Payne E., Green C. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. International Journal of Geriatric Psychiatry 2006, 21:17-28.
427. Taragano F.E., Lyketsos C.G., Mangone C.A., Allegri R.F., Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997, 38:246-252.
428. Tauscher J., Verhoeff N.P., Christensen B.K., Hussey D., Meyer J.H., Kecojevic A., Javanmard M., Kasper S., Kapur S. Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET. Neuropsychopharmacology 2001, 24:522-530.
429. Terry A.V., Buccafusco J.J., Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behavioural Brain Research 2008, 195:30-38.
430. Thomas A.J., Hendriksen M., Piggott M., Ferrier I.N., Perry E., Ince P., O'Brien J.T. A study of the serotonin transporter in the prefrontal cortex in late-life depression and Alzheimer's disease with and without depression. Neuropathology and Applied Neurobiology 2006, 32:296-303.
431. Thompson P.M., Mega M.S., Woods R.P., Zoumalan C.I., Lindshield C.J., Blanton R.E., Moussai J., Holmes C.J., Cummings J.L., Toga A.W. Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cerebral Cortex 2001, 11:1-16.
432. Thompson S., Lanctot K.L., Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opinion on Drug Safety 2004, 3:425-440.
433. Toda N., Kaneko T., Kogen H. Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter. Chemical & Pharmaceutical Bulletin 2010, 58:273-287.
434. Toda N., Tago K., Marumoto S., Takami K., Ori M., Yamada N., Koyama K., Naruto S., Abe K., Yamazaki R., Hara T., Aoyagi A., Abe Y., Kaneko T., Kogen H. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorganic & Medicinal Chemistry 2003, 11:1935-1955.
435. Tohgi H., Abe T., Takahashi S., Kimura M., Takahashi J., Kikuchi T. Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neuroscience Letters 1992, 141:9-12.
436. Tohgi H., Abe T., Takahashi S., Saheki M., Kimura M. Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administration of citalopram, a synthetic serotonin uptake inhibitor. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 1995, 9:121-131.
437. Truchot L., Costes N., Zimmer L., Laurent B., Le Bars D., Thomas-Anterion C., Mercier B., Hermier M., Vighetto A., Krolak-Salmon P. A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease. NeuroImage 2008, 40:1251-1256.
438. Truchot L., Costes S.N., Zimmer L., Laurent B., Le Bars D., Thomas-Anterion C., Croisile B., Mercier B., Hermier M., Vighetto A., Krolak-Salmon P. Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology 2007, 69:1012-1017.
439. Tsang S.W., Keene J., Hope T., Spence I., Francis P.T., Wong P.T., Chen C.P., Lai M.K. A serotoninergic basis for hyperphagic eating changes in Alzheimer's disease. Journal of the Neurological Sciences 2010, 288:151-155.
440. Tsang S.W., Lai M.K., Francis P.T., Wong P.T., Spence I., Esiri M.M., Keene J., Hope T., Chen C.P. Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients. Neuroreport 2003, 14:1297-1300.
441. Tsukada H., Kakiuchi T., Nishiyama S., Ohba H., Harada N. Effects of aging on 5-HT(1A) receptors and their functional response to 5-HT(1a) agonist in the living brain: PET study with [carbonyl-(11)C]WAY-100635 in conscious monkeys. Synapse 2001, 42:242-251.
442. 1A receptor binding in patients with homozygous D90A SOD1 vs sporadic ALS. Neurology 2007, 68:1233-1235.
443. Turner M.R., Rabiner E.A., Hammers A., Al-Chalabi A., Grasby P.M., Shaw C.E., Brooks D.J., Leigh P.N. [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain 2005, 128:896-905.
444. Uchida S., Umeeda H., Kitamoto A., Masushige S., Kida S. Chronic reduction in dietary tryptophan leads to a selective impairment of contextual fear memory in mice. Brain Research 2007, 1149:149-156.
445. Ueda S., Sakakibara S., Yoshimoto K. Effect of long-lasting serotonin depletion on environmental enrichment-induced neurogenesis in adult rat hippocampus and spatial learning. Neuroscience 2005, 135:395-402.
446. Upton N., Chuang T.T., Hunter A.J., Virley D.J. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 2008, 5:458-469.
447. van Dyck C.H., Malison R.T., Seibyl J.P., Laruelle M., Klumpp H., Zoghbi S.S., Baldwin R.M., Innis R.B. Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. Neurobiology of Aging 2000, 21:497-501.
448. van Luijtelaar M.G., Steinbusch H.W., Tonnaer J.A. Aberrant morphology of serotonergic fibers in the forebrain of the aged rat. Neuroscience Letters 1988, 95:93-96.
449. van Luijtelaar M.G., Tonnaer J.A., Steinbusch H.W. Aging of the serotonergic system in the rat forebrain: an immunocytochemical and neurochemical study. Neurobiology of Aging 1992, 13:201-215.
450. van Luijtelaar M.G., Steinbusch H.W., Tonnaer J.A. Similarities between aberrant serotonergic fibers in the aged and 5,7-DHT denervated young adult rat brain. Experimental Brain Research 1989, 78:81-89.
451. Venero J.L., de la Roza C., Machado A., Cano J. Age-related changes on monoamine turnover in hippocampus of rats. Brain Research 1993, 631:89-96.
452. 1A receptors in the rat hippocampus. Neurobiology of Aging 2011, 32:103-114.
453. Verkhratsky A., Olabarria M., Noristani H.N., Yeh C.Y., Rodriguez J.J. Astrocytes in Alzheimer's disease. Neurotherapeutics 2010, 7:399-412.
454. 2A system: age-, gender-, and Alzheimer's disease-related findings. Neurobiology of Aging 2003, 24:553-561.
455. Vertes R.P. Brainstem afferents to the basal forebrain in the rat. Neuroscience 1988, 24:907-935.
456. Vertes R.P. A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. The Journal of Comparative Neurology 1991, 313:643-668.
457. Vertes R.P., Crane A.M. Distribution, quantification, and morphological characteristics of serotonin-immunoreactive cells of the supralemniscal nucleus (B9) and pontomesencephalic reticular formation in the rat. The Journal of Comparative Neurology 1997, 378:411-424.
458. Vertes R.P., Fortin W.J., Crane A.M. Projections of the median raphe nucleus in the rat. The Journal of Comparative Neurology 1999, 407:555-582.
459. Vialli M., Erspamer V. Ricerche sul secreto delle cellule enterocromaffini. Zeitschrift für Zellforschung und Mikroskopische Anatomie Abt 1937-38, 27:81-99.
460. Vialli M., Erspamer V. Sulle reazioni chimiche colorste deli' enteramins. Nota I. Ricerche su estratti scetonici di mucosa gastrointestinale. Archivio Di Scienze Biologiche 1942, 28:101-121.
461. Wallin A., Alafuzoff I., Carlsson A., Eckernas S.A., Gottfries C.G., Karlsson I., Svennerholm L., Winblad B. Neurotransmitter deficits in a non-multi-infarct category of vascular dementia. Acta Neurologica Scandinavica 1989, 79:397-406.
462. Wang S.J., Wang K.Y., Wang W.C., Sihra T.S. Unexpected inhibitory regulation of glutamate release from rat cerebrocortical nerve terminals by presynaptic 5-hydroxytryptamine-2A receptors. The Journal of Neuroscience Research 2006, 84:1528-1542.
463. Weber L.J., Angell L.A. Hyperthermia and elevated brain 5-hydroxytryptamine of rabbits in response to tryptophan and 5-hydroxytryptophan infusion. Biochemical Pharmacology 1967, 16:2451-2454.
464. Welsh S.E., Kachelries W.J., Romano A.G., Simansky K.J., Harvey J.A. Effects of LSD, ritanserin, 8-OH-DPAT, and lisuride on classical conditioning in the rabbit. Pharmacology, Biochemistry, and Behavior 1998, 59:469-475.
465. 6 receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience 2009, 164:692-701.
466. Wester P., Hardy J.A., Marcusson J., Nyberg P., Winblad B. Serotonin concentrations in normal aging human brains: relation to serotonin receptors. Neurobiology of Aging 1984, 5:199-203.
467. Whitaker-Azmitia P.M., Murphy R., Azmitia E.C. Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Research 1990, 528:155-158.
468. Wilcock G.K., Esiri M.M., Bowen D.M., Hughes A.O. The differential involvement of subcortical nuclei in senile dementia of Alzheimer's type. Journal of Neurology, Neurosurgery, and Psychiatry 1988, 51:842-849.
469. Williams G.V., Rao S.G., Goldman-Rakic P.S. The physiological role of 5-HT2A receptors in working memory. The Journal of Neuroscience 2002, 22:2843-2854.
470. Willins D.L., Deutch A.Y., Roth B.L. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 1997, 27:79-82.
471. Wilson M.A., Ricaurte G.A., Molliver M.E. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 1989, 28:121-137.
472. Wolff M., Costet P., Gross C., Hen R., Segu L., Buhot M.C. Age-dependent effects of serotonin-1A receptor gene deletion in spatial learning abilities in mice. Brain Research. Molecular Brain Research 2004, 130:39-48.
473. Wong D.F., Wagner H.N., Dannals R.F., Links J.M., Frost J.J., Ravert H.T., Wilson A.A., Rosenbaum A.E., Gjedde A., Douglass K.H., et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984, 226:1393-1396.
474. Wong E.H., Reynolds G.P., Bonhaus D.W., Hsu S., Eglen R.M. Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders. Behavioural Brain Research 1996, 73:249-252.
475. Woolf N.J., Butcher L.L. Cholinergic systems in the rat brain: IV. Descending projections of the pontomesencephalic tegmentum. Brain Research Bulletin 1989, 23:519-540.
476. Woolley M.L., Bentley J.C., Sleight A.J., Marsden C.A., Fone K.C. A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001, 41:210-219.
477. Xu Y., Yan J., Zhou P., Li J., Gao H., Xia Y., Wang Q. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Progress in Neurobiology 2012, 97:1-13.
478. Yamamoto M., Suhara T., Okubo Y., Ichimiya T., Sudo Y., Inoue M., Takano A., Yasuno F., Yoshikawa K., Tanada S. Age-related decline of serotonin transporters in living human brain of healthy males. Life Sciences 2002, 71:751-757.
479. Yamamoto T., Hirano A. Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. Annals of Neurology 1985, 17:573-577.
480. Yasumatsu M., Yazawa T., Otokawa M., Kuwasawa K., Hasegawa H., Aihara Y. Monoamines, amino acids and acetylcholine in the preoptic area and anterior hypothalamus of rats: measurements of tissue extracts and in vivo microdialysates. Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology 1998, 121:13-23.
481. Yau J.L., Olsson T., Noble J., Seckl J.R. Serotonin receptor subtype gene expression in the hippocampus of aged rats following chronic amitriptyline treatment. Brain Research. Molecular Brain Research 1999, 70:282-287.
482. Yeung L.Y., Kung H.F., Yew D.T. Localization of 5-HT1A and 5-HT2A positive cells in the brainstems of control age-matched and Alzheimer individuals. Age (Dordrecht, Netherlands) 2010, 32:483-495.
483. Yew D.T., Yeung L.Y., Wai M.S., Mak Y.T. 5-HT 1A and 2A receptor positive cells in the cerebella of mice and human and their decline during aging. Microscopy Research and Technique 2009, 72:684-689.
484. Zhang L., Guadarrama L., Corona-Morales A.A., Vega-Gonzalez A., Rocha L., Escobar A. Rats subjected to extended L-tryptophan restriction during early postnatal stage exhibit anxious-depressive features and structural changes. Journal of Neuropathology and Experimental Neurology 2006, 65:562-570.
485. Zhou F.C., Azmitia E.C., Bledsoe S. Rapid serotonergic fiber sprouting in response to ibotenic acid lesion in the striatum and hippocampus. Brain Research Development. Brain Research 1995, 84:89-98.
486. Zhuo M., Gebhart G.F. Spinal serotonin receptors mediate descending facilitation of a nociceptive reflex from the nuclei reticularis gigantocellularis and gigantocellularis pars alpha in the rat. Brain Research 1991, 550:35-48.
487. Zweig R.M., Ross C.A., Hedreen J.C., Steele C., Cardillo J.E., Whitehouse P.J., Folstein M.F., Price D.L. The neuropathology of aminergic nuclei in Alzheimer's disease. Annals of Neurology 1988, 24:233-242.